| Description | Norswertianolin, a compound isolated from G. acuta, functions as a CSE activator and shows promise as a potential cardiovascular therapeutic. |
| In vitro | Norswertianolin (3.125~50 μM; H9c2 cells) has the protective effects on H 2 O 2 -induced H9c2 cells. Norswertianolin significantly increases the transcription levels of HO-1 and GCLC in H9c2 cells[1]. Norswertianolin (0~150 μM; HepG2 cells) high concentration increases the CSE protein level[2]. |
| In vivo | Norswertianolin (4.4 mg/kg/day; s.c.; 1 week) improves CSE/H 2 S production[2]. Norswertianolin treatment attenuates the renal tubular injury in acute I/R. Norswertianolin also reduces I/R-stimulated ROS by DHE fluorescence intensity. Norswertianolin has anti-hypertension effects, inhibits vascular remodeling and reduces inflammation effects[2]. Animal Model: Male Sprague Dawley rats (10~12 weeks)[2]Dosage: 4.4 mg/kg/day Administration: S.c. Result: Improved CSE/H 2 S production. |
| molecular weight | 422.34 |
| Molecular formula | C19H18O11 |
| CAS | 54954-12-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Ren K, et al. Effects of Four Compounds from Gentianella acuta (Michx.) Hulten on Hydrogen Peroxide-Induced Injury in H9c2 Cells. Biomed Res Int. 2019;2019:2692970. Published 2019 Jan 20. 2. Niu Y, et al. Norswertianolin Promotes Cystathionine γ-Lyase Activity and Attenuates Renal Ischemia/Reperfusion Injury and Hypertension. Front Pharmacol. 2021;12:677212. Published 2021 Jul 14. doi:10.3389/fphar.2021.677212 |